Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nuo Therapeutics ( (AURX) ) just unveiled an announcement.
On December 16, 2025, Nuo Therapeutics held its Annual Meeting of Stockholders, where key corporate governance matters were voted on, including the election of four directors, the ratification of MaloneBailey LLP as the company’s external accounting firm, and the advisory approval of executive officer compensation. These decisions signify continuity in leadership and operational oversight for the fiscal year 2025, reflecting shareholder engagement and strategic alignment, which could have implications for the company’s stability and stakeholder confidence.
The most recent analyst rating on (AURX) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Nuo Therapeutics stock, see the AURX Stock Forecast page.
More about Nuo Therapeutics
Nuo Therapeutics, Inc. operates in the healthcare sector and specializes in regenerative therapies, focusing on innovative technologies that support healing processes and enhanced treatment outcomes.
Average Trading Volume: 4,664
Technical Sentiment Signal: Buy
Current Market Cap: $96.16M
For detailed information about AURX stock, go to TipRanks’ Stock Analysis page.